glenmark: Glenmark Chief on Cracking the Multi-Specific Code
Glenmark Chairman and Managing Director Glen Saldanha, along with Vikas Dandekar and Rica Bhattacharyya, discuss the company’s 25-year innovation drive and why it has finally come to fruition. At the center is ISB2001, a tri-specific antibody in partnership with AbbVie, born from Glenmark’s IGI platform after fifteen years of R&D. Saldanha explains the trajectory of the platform, why Glenmark is staying out of ADCs and CAR-T, how it is creating “Glenmark 3.0” in oncology, dermatology and respiratory, and why it continues to move in this direction.…Read moreI would rate the US well ahead of China on innovation. The conversation also covers India’s licensing deals with Chinese biotechnology, artificial intelligence in drug discovery and the GLP-1 market.
